<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245530</url>
  </required_header>
  <id_info>
    <org_study_id>INM-176</org_study_id>
    <nct_id>NCT01245530</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia</brief_title>
  <official_title>Probable Alzheimer Type Dementia Compare INM-176 1200~1600mg/Day With Donepezil 5~10mg/Day of Safety and Efficacy to Randomization, Multicenter, Double-blind, Double-dummy, Parallel Phase III Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Whanin Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Whanin Pharmaceutical Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of two fixed dose
      (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil
      for treatment for patients with Alzheimer type dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probable Alzheimer type dementia compare INM-176 1200~1600mg/day with Donepezil 5~10mg/day of
      safety and efficacy to randomization, multicenter, double-blind, double-dummy, parallel Phase
      III clinical study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognition as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) total score</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Mini-Mental State Examination (MMSE)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Clinical Dementia Rating</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Global Deterioration Scale(GDS)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Korean Activity of Living(K-IADL)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Korean Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Alzheimer Type Dementia</condition>
  <arm_group>
    <arm_group_label>Aricept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: Aricept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INM-176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: INM-176</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aricept</intervention_name>
    <description>Aricept Comparator Intervention: Drug: Aricept 5~10 mg orally every day for 24weeks</description>
    <arm_group_label>Aricept</arm_group_label>
    <other_name>Donepezil HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INM-176</intervention_name>
    <description>INM-176: Experimental Intervention: Drug:INM-176 600~1200 mg orally every day for 24weeks</description>
    <arm_group_label>INM-176</arm_group_label>
    <other_name>KR-WAP-026</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age range : 50 ~ 80 years old

          2. Informed consent signed and dated by patient or legal representative

          3. Subjects diagnosed with Alzheimer's disease according to DSM-IV criteria

          4. Subjects diagnosed with probable Alzheimer's disease according to the National
             Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and
             Related Disorders Association (NINCDS-ADRDA) criteria

          5. MMSE score 10 to 26

          6. CDR(Clinical Dementia Rating) score 1~2 or GDS(Global Deterioration Scale) 3~5 stage

          7. Subjects who didn't take any medication for AchEI (donepezil, memantine, galantamin,
             etc) before treating or can stop medication at least 4 weeks more prior to screening
             visit

          8. Subjects menopause women or her/his spouse consent with contraception during the study
             period and 90 days after end of study

        Exclusion Criteria:

          1. Subjects with psychiatric disorders other than Alzheimer's disease, such as
             schizophrenia, depression, bipolar disorder, etc

          2. Subjects diagnosed or accompanied with Dementia due to other Neurodegenerative
             disorders (AIDS, syphilis, creutzfeldt-jacob disease, Picks Disease, Huntingtons
             Disease, Parkinsons disease related dementia)

          3. Subjects diagnosed with vascular dementia

          4. Subjects diagnosed with stroke within last 3 months prior to screening visit

          5. Subjects who have medical history of significant hepatic disease in screening visit (2
             ULN≤ALT, AST)

          6. Subjects who have medical history of significant renal disease in screening visit
             (1.5mg/dl≤Serum creatinine)

          7. Subjects who have difficult with regulating blood glucose level with anti-diabetes
             drug (8.0%&lt;HbA1c)

          8. Subjects who have medical history of myocardial infarction or arrhythmia

          9. Subjects who take warfarin with Atrial fibrillation

         10. Pregnant or nursing women

         11. Subjects who p0articipated in other clinical trail within last 3 months

         12. Subjects who have hypersensitivity to AchEl (acetylcholinesterase inhibitor)

         13. Subjects who have unstable clinical laboratory result in screening visit

         14. Subjects doubted the pulmonary disease on the chest X-ray in screening visit

         15. Subjects considered unsuitable to participate in clinical trail by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SangYoon Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Whanin Pharm.Co.,Ltd.</name>
      <address>
        <city>Seoul</city>
        <state>Moonjung</state>
        <zip>138-200</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2010</study_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Heesook Nam</name_title>
    <organization>Whanin Pharmaceutical Company</organization>
  </responsible_party>
  <keyword>Alzheimer disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

